News & Updates

Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.

Management of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed from androgen deprivation therapy (ADT) alone to the addition of chemotherapy and androgen receptor pathway inhibitors (ARPIs) to create more efficacious treatment regimens. At an industry-sponsored meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the Department of Urology, University of Lübeck in Germany, and Ms Helen Chan, Principal Pharmacist of the Chinese University of Hong Kong Medical Centre in Hong Kong, explored how ARPI-associated advances can further optimize outcomes, not only by improving survival, but also by maintaining health-related quality of life (HRQoL) and minimizing adverse events (AEs) and critical drug–drug interactions (DDIs).

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown.